<DOC>
	<DOCNO>NCT02597933</DOCNO>
	<brief_summary>Systemic Sclerosis ( SSc ) devastate disease unknown etiology . Patients suffer multiple organ fibrosis whereas lung fibrosis ( interstitial lung disease , ILD ) one main driver mortality . There preclinical evidence efficacy nintedanib SSc associate ILD ( SSc-ILD ) anti-fibrotic efficacy nintedanib proven idiopathic pulmonary fibrosis patient , present similar pattern regard lung fibrosis . Hence purpose trial confirm efficacy safety nintedanib 150 mg bid treat patient SSc-ILD , compare placebo . The trial conduct double blind , randomise , placebo-controlled trial primary efficacy evaluation week 52 placebo-controlled treatment last patient ( maximum 100 week ) . Respiratory function globally accept assessment treatment effect patient lung fibrosis . The chosen endpoint ( Forced Vital Capacity ( FVC ) decline ) easy obtain part usual examination do patient SSc-ILD .</brief_summary>
	<brief_title>A Trial Compare Nintedanib With Placebo Patients With Scleroderma Related Lung Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<criteria>Inclusion criterion : Age &gt; = 18 year 2013 ACR / EULAR classification criterion SSc fulfil SSc disease onset ( define first nonRaynaud symptom ) within 5 year SSc relate Interstitial Lung Disease confirm HRCT ; Extent fibrotic disease lung &gt; = 10 % FVC &gt; = 40 % predict normal DLCO 30 % 89 % predict normal Exclusion criterion : AST , ALT &gt; 1.5 x ULN Bilirubin &gt; 1.5 x ULN Creatinine clearance &lt; 30 mL/min Airway obstruction ( prebronchodilator FEV1/FVC &lt; 0.7 ) Other clinically significant pulmonary abnormality Significant PH Cardiovascular diseases More 3 digital fingertip ulcer history severe digital necrosis require hospitalization severe ulcer Bleeding risk ( predisposition bleeding , fibrinolysis , fulldose anticoagulation , high dose antiplatelet therapy , history hemorrhagic central nervous system ( CNS ) event within last year international normalise ratio ( INR ) &gt; 2 , prolongation prothrombin time ( PT ) partial thromboplastin time ( PTT ) &gt; 1.5 x ULN ) History thrombotic event within last year Clinical sign malabsorption need parenteral nutrition Previous treatment nintedanib pirfenidone Treatment prednisone &gt; 10 mg/day , azathioprine , hydroxychloroquine , colchizine , Dpenicillamine , sulfasalazine , cyclophosphamide , rituximab , tocilizumab , abatacept , leflunomide , tacrolimus , new antiarthritic treatment like tofacitinib ciclosporine A , potassium paraaminobenzoate Unstable background therapy either mycophenolate mofetil methotrexate Previous plan hematopoietic stem cell transplantation Patients underlie chronic liver disease ( Child Pugh A , B , C hepatic impairment )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>